Nektar Therapeutics (NKTR)
NKTR Stock Price Chart
Explore Nektar Therapeutics interactive price chart. Choose custom timeframes to analyze NKTR price movements and trends.
NKTR Company Profile
Discover essential business fundamentals and corporate details for Nektar Therapeutics (NKTR) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
3 May 1994
Employees
61.00
Website
https://www.nektar.comCEO
Howard W. Robin
Description
Nektar Therapeutics is a biopharmaceutical firm dedicated to the global discovery and advancement of therapies addressing significant unmet medical requirements. Central to its robust pipeline is Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist. This drug is currently in Phase 3 clinical trials for metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, head and neck squamous cell carcinoma, and adjuvant melanoma. It is also being evaluated in Phase 2 for renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; Phase 1/2A for head and neck squamous cell carcinoma; Phase 1/2 for various solid tumors; and Phase 1B for COVID-19. Additionally, Nektar is developing NKTR-358, a cytokine Treg stimulant, which is in Phase 2 trials for systemic lupus erythematosus and ulcerative colitis, and Phase 1B for atopic dermatitis and psoriasis. Their portfolio further includes NKTR-255, an IL-15 receptor agonist, undergoing Phase 1/2 trials for non-Hodgkin's lymphoma, multiple myeloma, head and neck cancer, and colorectal cancer. Another investigational compound, NKTR-262, a toll-like receptor agonist, is in Phase 1/2 trials for solid tumors. The company is also advancing several other drug candidates. Nektar Therapeutics maintains strategic collaboration agreements with a multitude of pharmaceutical entities, including Takeda Pharmaceutical Company Ltd., AstraZeneca AB, UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Bausch Health Companies Inc., Pfizer Inc., Amgen Inc., UCB Pharma (Biogen), Bristol-Myers Squibb Company, Baxalta Incorporated, Eli Lilly and Company, Merck KGaA, and SFJ Pharmaceuticals, Inc. Established in 1990, Nektar Therapeutics is headquartered in San Francisco, California.
NKTR Financial Timeline
Browse a chronological timeline of Nektar Therapeutics corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is -$1.94, while revenue estimate is $10.33m.
Earnings released on 7 May 2026
EPS came in at -$1.82 falling short of the estimated -$1.58 by -15.02%, while revenue for the quarter reached $10.86m , beating expectations by +1.59%.
Earnings released on 12 Mar 2026
EPS came in at -$1.78 surpassing the estimated -$2.76 by +35.51%, while revenue for the quarter reached $21.81m , beating expectations by +114.01%.
Earnings released on 6 Nov 2025
EPS came in at -$1.85 surpassing the estimated -$2.85 by +35.09%, while revenue for the quarter reached $11.79m , beating expectations by +12.94%.
Earnings released on 7 Aug 2025
EPS came in at -$2.95 surpassing the estimated -$3.13 by +5.75%, while revenue for the quarter reached $11.18m , beating expectations by +18.68%.
Stock split effective on 9 Jun 2025
Shares were split 1 : 15 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 8 May 2025
EPS came in at -$3.30 falling short of the estimated -$2.70 by -22.22%, while revenue for the quarter reached $10.46m , missing expectations by -31.88%.
Earnings released on 12 Mar 2025
EPS came in at -$2.25 falling short of the estimated -$1.95 by -15.38%, while revenue for the quarter reached $29.18m , missing expectations by -20.41%.
Earnings released on 7 Nov 2024
EPS came in at -$0.18 surpassing the estimated -$0.23 by +21.74%, while revenue for the quarter reached $24.12m , missing expectations by -23.15%.
Earnings released on 8 Aug 2024
EPS came in at -$0.25 falling short of the estimated -$0.21 by -19.05%, while revenue for the quarter reached $23.49m , beating expectations by +33.92%.
Earnings released on 9 May 2024
EPS came in at -$0.18 surpassing the estimated -$0.21 by +14.29%, while revenue for the quarter reached $21.64m , beating expectations by +41.06%.
Earnings released on 4 Mar 2024
EPS came in at -$0.22 falling short of the estimated -$0.20 by -10.00%, while revenue for the quarter reached $23.89m , beating expectations by +32.33%.
Earnings released on 7 Nov 2023
EPS came in at -$0.19 falling short of the estimated -$0.18 by -5.56%, while revenue for the quarter reached $24.14m , beating expectations by +29.67%.
Earnings released on 8 Aug 2023
EPS came in at -$0.27 surpassing the estimated -$0.30 by +10.00%, while revenue for the quarter reached $20.50m , missing expectations by -5.92%.
Earnings released on 9 May 2023
EPS came in at -$0.25 surpassing the estimated -$0.26 by +3.85%, while revenue for the quarter reached $21.59m , beating expectations by +4.93%.
Earnings released on 28 Feb 2023
EPS came in at -$0.32 surpassing the estimated -$0.45 by +28.89%, while revenue for the quarter reached $22.02m , missing expectations by -0.51%.
Earnings released on 3 Nov 2022
EPS came in at -$0.24 surpassing the estimated -$0.47 by +48.94%, while revenue for the quarter reached $23.63m , beating expectations by +4.50%.
Earnings released on 4 Aug 2022
EPS came in at -$0.85 surpassing the estimated -$1.01 by +15.84%, while revenue for the quarter reached $21.59m , missing expectations by -4.56%.
Earnings released on 5 May 2022
EPS came in at -$0.49 surpassing the estimated -$0.72 by +31.94%, while revenue for the quarter reached $24.82m , beating expectations by +2.16%.
Earnings released on 28 Feb 2022
EPS came in at -$0.79 surpassing the estimated -$0.81 by +2.47%, while revenue for the quarter reached $25.01m , missing expectations by -27.01%.
Earnings released on 4 Nov 2021
EPS came in at -$0.70 surpassing the estimated -$0.80 by +12.50%, while revenue for the quarter reached $24.92m , missing expectations by -10.42%.
Earnings released on 5 Aug 2021
EPS came in at -$0.69 surpassing the estimated -$0.72 by +4.17%, while revenue for the quarter reached $28.33m , beating expectations by +9.05%.
NKTR Stock Performance
Access detailed NKTR performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
